anti-CLEC9A antibody product blog
Tags: Antibody; Monoclonal Antibody; CLEC9A; anti-CLEC9A antibody;
The CLEC9A clec9a (Catalog #MBS642820) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The CLEC9a (C-type Lectin Domain Family 9 Member A, UNQ9341/PRO34046) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s CLEC9a can be used in a range of immunoassay formats including, but not limited to, Flow Cytometry (FC/FACS).Suitable for use in Flow Cytometry.
Dilution: Flow Cytometry: 2.5ug labels 10e6 cells. Researchers should empirically determine the suitability of the CLEC9A clec9a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The CLEC9A clec9a product has the following accession number(s) (GI #46409326) (NCBI Accession #NP_997228.1) (Uniprot Accession #Q6UXN8). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
CLEC9a also known as DNGR-1, is a type II transmembrane glycoprotein member of the C-type lectin superfamily. Mature human CLEC9a consists of a 35aa cytoplasmic domain with an ITAM-like motif, a 21aa transmembrane segment, and a 185 extracellular domain (ECD) that contains a stalk region and one C-type lectin domain (CTLD). Within the ECD, human CLEC9a shares 57% aa sequence identity with mouse and rat CLEC9a. Although the CTLD of CLEC9a structurally resembles that of other C-type lectins, it lacks the conserved residues that typically mediate calcium and carbohydrate binding. CLEC9a is expressed as a disulfide-linked homodimer of ~45-50kD N-glycosylated subunits. Human CLEC9a expression is restricted to a subpopulation of BDCA-3+ conventional dendritic cells (cDC) and CD16- monocytes. BDCA-3+ cDC are analagous to mouse CD8+ cDC which are specialized in antigenic cross-presentation in complex with MHC class I molecules. In mouse, CLEC9a is additionally expressed on plasmacytoid dendritic cells. CLEC9a ligation enhances antigen uptake and processing, leading to presentation on MHC class I and cytotoxic T cell (CTL) priming. In mouse, CLEC9a recognizes normally intracellular determinant(s) of necrotic cells and mediates their uptake by the dendritic cell. The subsequent antigenic cross-presentation to CTL is important for clearing necrotic cellular debris. CLEC9a signaling triggers activation of the tyrosine kinase Syk.
Immunogen: Recombinant corresponding to human CLEC9a expressed in NS0 cell line.
Endotoxin Level: ~0.10EU/ug (LAL). In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CLEC9A are readily searchable from our website. Different antibodies against the same target such as CLEC9A may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.